/	FORMULAS IN
(AUG 1 5 2003 2
18	A TRADEMART

FORMATION DISCLOSURE STATEMENT

IN AN APPLICATION

Docket Number:	Application Number
11669.115USWO	09/700.806

• .				Date Mailed:	AUGUST	15, 2003	Sheet 1	of 2
P.E.	NFORMATION DI	SCLOSURE STATEM	IENT	Docket Number: 11669.115USWO		1	tion Number:	2
in an application				Applicant: Ben-Qu	an Shen	L	否.	E C
1 5 2000 2	(Use several	sheets if necessary)		Filing Date: 3/12/2	002	Group A	rt Unit: 1547	8- C
				Customer No: 235	52		1/2	0
& TRADE							art Unit: 7547	100
	**************************************		U.S. PATENT DOCUM	MENTS				930
EXAMINER INITIAL	DOCUMENT N	O. DATE	NAME	CLASS	SUBC	CLASS	FILING IF APPRO	DATE
			ODDICK DATES DO		1			
	DOCUMENT N	<u> </u>	COUNTRY	CLASS	SITE	CLASS	TDANICI	ATION
	DOCOMBIA!	DAIL DAIL	COUNTRY	CLASS	3000	-LAGO	YES	LATION
RBK	·75,444		Europe				- 55	
RBIL	36,776		Europe					
		OTHER DOCUME	NTS (Including Author, Ti	itle, Date, Pertinent Pa	ges, Etc.)			
RBV	Boli Cons	var et al., Gene, 2:95-11 struction and Characteri	3 (1977) zation of New Cloning Ve	ehicles				
	^T Cohe Non	en, Proc. Natl. Acad. Sc chromosomal Antibiotic	i., (USA), 69:8, 2110-211 c Resistance in Bacteria: (4 (1972) Genetic Transformatio	n of <i>Escheri</i>	chia coli b	y R-Factor DN/	\
		et al., Nature, 273:113 plete Nucleotide Seque					*	
	Dire		ichia coli of a NDA Seque		n Growth H	ormone		
	Goed Synt	ldel et al., Nucleic Acid hesis of Human Fibrobl	is Res., 8:18, pp. 4057-407 last Interferon by E. coli	74 (1980)				·····
	Grah A No	am and van der Eb, Vir w Technique for the A	rology, 52:456-467 (1978) ssay of Infectivity of Hum	nan Adenovirus 5 DNA	\			
	Isola	tion and Characterization	m., 255:24, pp. 2073-120 on of the Yeast 3-Phospho	80 (1980) oglycerokinase Gene (PGK) by an	Immunolo	gical Screening	Technique
	Hess Coop	et al., J. Adv. Enzyme peration of Glycolytic E	Reg., 7:149-167 (1968) inzymes					
	Isola	Holland et al., Biochemistry, 17:23, pp. 4900-4907 (1978) Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enclase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase						
	Hsia High	o et al., Proc. Natl. Aca -frequency Transforma	d. Sci. (USA), 76:8, pp.38 tion of Yeast by Plasmids	29-3833 (1979) Containing the Clined	Yeast ARG	⁴ Gene		·
	Iden		Activity and the Cloning	and Expression of Pla	telet-derived	l Endotheil	ial Cell Growth	Factor
	Expr		oli of a Chemically Synthe	sized Gene for the Hor	rmone Soma	tostatin		
rbic		s, Genetics, 85:23-33 (1 inase Mutants of Sacch						

EXAMINER RAULU B.	Kann	DATE CONSIDERED	12/10/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Date Mailed: AUGUST 15, 2003

Sheet 2 of 2

FOI	RM	14	49*	
/	P	7		IN
O			- 4	
AUG	_		~~~	الة ا

FORMATION DISCLOSURE STATEMENT

Docket Number: 11669.115USWO Application Number: 09/700,806

101, E 43			03/700,000			
	IN AN APPLICATION	Applicant: Ben-Quan Shen	1 7			
AU6 1 5 2003	(Use several sheets if necessary)	Filing Date: 3/12/2002	Group Art Unit: 18	١,		
£/		Customer No: 23552	ट्रि क	沙		
TRADEWARK			THE TO	4		
RBK	Keyt et al., J. Biol. Chem., 271:10, pp. 5638-5646 Identification of Vascular Endothelial Growth Fac	5 (1996) ctor Determinants for Binding KDR a	nd FLT-1 Receptors E Yeast trpl Region			
	Kingsman et al., Gene 7:141-152 (1979) Replication in Saccharomyces Cerevisiase of Plas		e Yeast trpl Region			
	Kunkel et al., Meth. Enzym. 204:125-139 (1991) Efficient Site-Directed Mutagenesis Using Uracil	-Containing DNA				
,	Laboratory Investigation, 72:615 (1995) Vascular Endothelial Growth Factor					
	Oates, Chapter 33, Goodman and Gilman, 9th Edi Antihypertensive Agents and the Drug Therapy of	ition, pages 780-781. f Hypertension				
	Mandel et al., J. Mol. Biol., 53:159-162 (1970) Calcium-dependent Bacteriophase DNA Infection					
	Maxam et al., Methods of Enzymology, 65:499 (1 Sequencing End-Labeled DNA with Base-Specific	977) c Chemical Cleavages				
	Messing et al., Nucleic Acids res., 9:2, pp. 309-32 A System for Shotgun DNA Sequencing	21 (1981)				
	Siebenlist et al., Cell, 20:269-281 (1980) E. Coli RNA Polymerase Interacts Homologously	with Two Different Promoters				
	Stinchcomb et al., Nature, 282:39-43 (1979) Isolation and Characterisation of a Yeast Chromosomal Replicator					
	Tschumper et al., Gene, 10:157-166 (1980) Sequence of a Yeast DNA Fragment Containing a	Chromosomal Replicator and the TR	P1 Gene			
	Urlaub and Chasin, Proc. Natl. Acad. Sci. (USA), Isolation of Chinese Hamster Cell Mutants Deficie	77:4, pp. 4216-4220 (1980) ent in Dihydrofolate Reductase Activi	ty			
RBK	Van Solingen et al., J. Bact., 130:946-947 (1977) Fusion of Yeast Spheroplasts			į		

Rachul	3.	Kannet
	Rayund	Rachul B.

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

Sheet $\frac{1}{2}$ of $\frac{4}{2}$ FORM PTO-1449 Atty Docket No. Serial No. U.S. Dept. of Commerce P1735R1 09/700,806 Patent and Trademark Office Applicant LIST OF DISCLOSURES C Ben-Quan Shen et al. Filing Date (Use several sheets if necessary) Group 02 Nov 2000 **U.S. PATENT DOCUMENTS** Examiner nitials Document Number Date Name Class Subclass Filing Date RBY 3,773,919 20.11.73 Boswell, G RECEIVED 3,887,699 03.06.75 2 Yolles, S. 4,816,567 3 28.03.89 Cabilly et al. SEH 05 2002 4 5,545,806 13.08.96 Lonberg et al. 5 5,545,807 13.08.96 Surani et al. 5,569,825 29,10,96 Lonberg et al. TECH CENTER 1600/290b 5,625,126 29.04.97 Lonberg et al. 5,633,425 27.05.97 Lonberg et al. 5,661,016 RBK 26.08.97 Lonberg et al. FOREIGN PATENT DOCUMENTS Examiner Translation Initials Document Number Date Class Country Subclass Yes No RBIL 1,176,565 10 23.10.84 CANADA 25.08.82 11 058.481 EPO 12 158,277 16.10.85 EPO (ENGLISH ABSTRACT ATTATCHED) RBK 15.11.90 13 WO 90/13649 OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.) Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" The Journal of Immunology 147(1):86-95 (1991) RBY 14 Burgess and Maciag, "The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins" Annu. Rev. Biochem. 58:575-606 (1989) 15 Busse and Fleming., "Endothelial Dysfunction in Atherosclerosis." J. Vasc. Res. 33:181-194 (1996) 16 Cao, Yihai et al., "Heterodimers of Placenta Growth Factor/Vascular Endothelial Growth Factor." <u>J. Bio</u>, Chem. 271:3154-3162 (1996) 17 De Vries et al., "The fms-Like Tyrosine Kinase, A Receptor for Vascular Endothelial Growth Factor." Science, 255:989-991 (Feb 1992) 18 Drummond and Harrison., "eNOS-Overexpressing Mice: Too Much NO Makes the Blood Pressure Low." J. Clin. Invest, 102:2033-2034 (Dec 1998) 19 Ferrara and Davis-Smyth., "The Biology of Vascular Endothelial Growth Factor." Endocrine Reviews. 18(1):4-25 (1997) Ferrara and Henzel, "Pituitary Follicular Cells Secrete a Novel Heparin-binding Growth Factor Specific for Vascular Endothelial Cells" Biochem. & Biophys. Res. Comm. 161(2):851-858 (1989) 21 Fishwild et al., "High-Avidity Human IgGk Monoclonal Antibodies From a Novel Strain of Minilocus Transgenic Mice" Nature Biotechnology. 14(7):845-851 (Jul 1996) 22 Folkman., "Angiogenesis in Cancer, Vascular, Rheumatoid and Other Disease." <u>Nature Medicine.</u> 1(1):27-31 RBY (1995) 23 Examiner Date Considered Kannst Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation

if not in conformance and not considered. Include copy of this form with next communication to applicant.

.*	OIPE
ORM PTO-1449	- St. 0 3 202 G
LIST OF DISCLOSUR	IES CITED BY APPLICANT

Sheet 2

U.S. Dept. of Commerce

Patent and Trademark Office

Serial No. Atty Docket No. 09/700,806 P1735R1

Applicant

Ben-Quan Shen et al Filing Date

(Use several sheets if necessary)

FORM PTO-1449

(ι	JSE SE	verai sneets it necessary)	02 Nov 2000	CENTER 1600			
		OTHER DISCLOSURES (Including Author, Title, Date,					
RBK	24	Fuh et al., "Requirements for Binding and Signaling of the Kinas Endothelial Growth Factor." <u>J. Bio. Chem.</u> 273(18):11197-11204 (1	se Domain Receptor fo May 1, 1998)	r Vascular			
	25	Hariawala et al., "VEGF Improves Myocardial Blood Flow but Produ Hearts." <u>J. Surg. Res.</u> 63:77-82 (1996)	uces EDRF-Mediated Hy	potension in Porcine			
	26	Hood et al., "VEGF Upregulates ecNOS Message, Protein, and NO P. Am. J. Phys. 274:H1054-H1058 (1998)	roduction in Human En	dothelial Cells."			
	27	Hoogenboom and Winter, "By-Passing Immunisation: Human Antibodic VH Gene Segments Rearranged in Vitro" J. Mol. Biol. 227:381-388	es from Synthetic Rep (1992)	ertoires of Germlin			
	28	Houck et al., "The Vascular Endothelial Growth Factor Family: It species and Characterization of Alternative Splicing of RNA." Me	dentification of a Fo ol. Endocrinol, 5:180	urth Molecular 6-1814 (1991)			
1	29	Ishikawa et al., "Identification of Angiogenic Activity and the Platelet-Derived Endothelial Cell Growth Factor." Nature, 338:5		on of			
	30	Jin et al., "Novel Analog of Atrial Natriuretic Peptide Selectiv Diuresis and Natriuresis in Rats." <u>J. Clinical Investigation</u> . 9	ve for Receptor-A Pro 8(4):969-976 (Aug 15,	duces Increased 1996)			
	31	Jones et al., "Replacing the Complementarity-Determining Regions Mouse" Nature 321:522-525 (May 29, 1986)	s in a Human Antibody	with those from a			
	32	of Biological Chemistry 271(10):5638-5646 (1996)	by Site-Directed Mut	agenesis." <u>Journal</u>			
	33	Keyt et al., "The Carboxyl-terminal Domain (111-165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency" <u>Journal of Biological Chemistry</u> 271(13):7788-7795 (Mar 29, 1996)					
	34	Kroll et al., "VEGF-A Induces Expression of eNOS and iNOS in Endothelial Cells via VEGF Receptor-2 (KDR)." Biochem. & Biophys, Res. Comm. 252:743-746 (1998)					
	35	Langer., "Controlled Release of Macromolecules." Chemtech, 12:90	8-105 (Feb 1982)				
i	36	Leung et al., "Vascular Endothelial Growth Factor is a Secreted 246:1306-1309 (1989)	Angiogenic Mitogen"	Science			
	37	Liu et al., "Angiogenesis Activators and Inhibitors Differentia Caveolae Formation in Vascular Endothelial Cells." <u>J. Bio. Chem</u>					
	38	Lonberg and Huszar., "Human Antibodies From Transgenic Mice" Int 13(1):65-93 (1995)	ternational Reviews o	f Immunology			
	39	Lonberg et al., "Antigen-Specific Human Antibodies From Mice Com Modifications" Nature, 368(6474):856-859 (Apr 28, 1994)	mprising Four Distinc	t Genetic			
	40		Luscher., "Endogenous and Exogenous Nitrates and Their Role in Myocardial Ischaemia." <u>Br. J. Clin.</u> <u>Pharmacol.</u> (Suppl. 1) 34:29s-35s (1992)				
	41	Malavaud et al., "Activation of Flk-1/KDR Mediates Angiogenesis but not Hypotension." <u>Cardiovascular</u> Research. 36(2):276-281 (Nov 1997)					
	42	Marks et al., "By-Passing Immunization: Building High Affinity! Bio/Technology 10:779-783 (1992)	Human Antibodies by C	hain Shuffling"			
BV	43	Marks et al., "By-Passing Immunization: Human Antibodies From V-Mol. Biol. 222:581-597 (1991)	gene Libraries Displ	ayed On Phage" J.			
xamine	er «	Rarried B. Kapriet	12/10/200 3				

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

USCOMM-DC 80-398.

	_	_	
Sheet	3	٥f	4

FORM PTO-1449 LIST OF DISCLOSURES CITED BY APPLICANT

U.S. Dept. of Commerce Patent and Trademark Office Atty Docket No. P1735R1 Applicant Ben-Ouan Shen et al

(۱	Jse sev	reral sheets if necessary)	Filing Date 02 Nov 2000 PECH CENTER 1600/20			
		OTHER DISCLOSURES (Including Author, Title, Date	, Pertinent Pages, etc.)			
RBK	44	Matthews et al., "A Receptor Tyrosine Kinase cDNA Isolated from Hematopoietic Cells and Exhibiting Close Genetic Linkage to c- (1991)	m a Population of Enriched Primitive			
	45	Meyer et al., "A Novel Vascular Endothelial Growth Factor Enco Angiogenesis Via Signalling Through VEGFR-2 (KDR) but not VEGF EMBO Journal 18(2):363-374 (Jan 15, 1999)	R-1 (Flt-1) Receptor Tyrosine Kinases."			
	46	Migdal et al., "Neuropilin-1 is a Placenta Growth Factor-2 Rec 1998)				
	47	Morbidelli et al., "Nitric Oxide Mediates Mitogenic Effect of J. Physiol. 270:H411-H415 (1996)				
	48	Morrison et al., "Chimeric Human Antibody Molecules: Mouse Ant. Region Domains' <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (November)	igen-Binding Domains with Human Constant ber 1984)			
	49	Morrison, S., "Immunology: Success in Specification" Nature, 3	68(6474):812-813 (Apr 28, 1994)			
	50	Muller et al., "The Crystal Structure of Vascular Endothelial (Resolution: Multiple Copy Flexibility and Receptor Binding." <u>S</u>	tructure. 5(10):1325-1338 (Oct 15, 1997)			
1	51	Muller et al., "Vascular Endothelial Growth Factor: Crystal St: Kinase Domain Receptor Binding Site." <u>Proc. Natl. Acad. Sci. U</u>	<u>SA</u> 94(14):7192~7197 (Jul 8, 1997)			
$\int_{-\infty}^{\infty}$	·52	Murohara et al., "Nitric Oxide Synthase Modulates Angiogenesis Invest. 101:2567-2578 (Jun 1998)				
	53	Nathan and Xie., "Regulation of Biosynthesis of Nitric Oxide."	J. Bio. Chem. 269:13725-13728 (May 1994)			
	54	Neuberger, M., "Generating High-Avidity Human Mabs in Mice" Nat	ture Biotechnology, 14(7):826 (Jul 1996)			
	55	Ogawa et al., "A Novel Type of Vascular Endothelial Growth Fact Utilizes KDR/Flk-1 Receptor and Carries a Potent Mitotic Activ: Bio. Chem. 273(47):31273-31282 (Nov 20, 1998)	ity Without Heparin-Binding Domain." J.			
	56	Ohashi et al., "Hypotension and Reduced Nitric Oxide-Elicited V Overexpressing Endothelial Nitric Oxide Synthase." J. Clin. Inv	<u>vest.</u> 102:2061-2071 (Dec 1998)			
	57	Olofsson et al., "Vascular Endothelial Growth Factor B (VEGF-B) Plasminogen Activator Activity in Endothelial Cells." <u>Proc. Nat</u> 29, 1998)	tl. Acad. Sci. USA 95(20):11709-11714 (Sep			
	58	Papapetropoulos et al., "Nitric Oxide Production Contributes to Endothelial Growth Factor in Human Endothelial Cells." J. Clin.	. <u>Invest.</u> 100:3131-3139 (Dec 1997)			
	59	Parenti et al., "Nitric Oxide is an Upstream Signal of Vascular Extracellular Signal-Regulated Kinase _{1/2} Activation in Postcapi 273:4220-4226 (Feb 1998)	llary Endothelium." <u>J. Bio, Chem.</u>			
	60	Pepper., "Manipulating Angiogenesis: From Basic Science to the Bio. 17:605-619 (1997)	Bedside." <u>Arterioscler. Thromb. Vasc.</u>			
	61	Presta, L., "Antibody Engineering" Curr. Op. Struct. Biol. 2:59				
	62	Riechmann et al., "Reshaping Human Antibodies for Therapy" Nature 332:323-327 (Mar 24, 1988)				
RBY	63	Rudic et al., "Direct Evidence for the Importance of Endotheliu Remodeling." <u>J. Clin. Invest.</u> 101:731-736 (Feb 1998)	um-Derived Nitric Oxide in Vascular			
Examine	r L	Parriet B. Kannot	Pate Considered			

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet	4	of	4

FORM PTO-1449 LIST OF DISCLOSURES STED BY (Use several sheets if necessary)

U.S. Dept. of Commerce Patent and Trademark Office Atty Docket No. P1735R1 **Applicant**

Ben-Quan Shen et al.

Filing Date

			02 Nov 2000	VEUH CENTED
		OTHER DISCLOSURES (Including Author, Title, Date,		YEUH CENTER 1600/2
RBIC	Sase and Michel., "Expression and Regulation of Endothelial Nitric Oxide Synthase." Trends Cardiova: 64 Med. 7:28-37 (1997)			Trends Cardiovasc.
	65			
	66	Shen et al., "Homologous Up-Regulation of KDR/Flk-1 Receptor Expression by Vascular Endothelial Growth Factor In Vitro." <u>J. Bio. Chem.</u> 273:29979-29985 (Nov 1998)		
	67	Shibuya et al., "Nucleotide Sequence and Expression of a Novel Human Receptor-Type Tyrosine Kinase General (flt) Closely Related to the fms Family." Oncogene 5:519-524 (1990)		
	68	Sidman et al., *Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid* <u>Biopolymers</u> 22(1):547-556 (1983)		
	69	Siemeister et al., "Expression of Biologically Active Isoforms of Escherichia coli." Biochem. & Biophys. Res. Comm. 222:249-255 (1)	of the Tumor Angioge 1996)	nesis Factor VEGF in
	70	Soker et al., "Neuropilin-1 is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor." <u>Cell.</u> 92:735-745 (Mar 1998)		
	71	Terman et al., "Identification of a New Endothelial Cell Growth Factor Receptor Tyrosine Kinase." Oncogene, 6:1677-1683 (1991)		
	72	Terman et al., "Identification of the KDR Tyrosine Kinase as a Receptor for Vascular Endothelial Cell Growth Factor." <u>Biochem. & Biophys. Res. Comm.</u> 187:1579-1586 (1992)		
	73	Tischer et al., "Vascular Endothelial Growth Factor: A New Member of the Platelet-Derived Growth Factor Gene Family," Biochem. & Biophys, Res. Comm. 165:1198-1206 (1989)		
	74	van der Zee et al., "Vascular Endothelial Growth Factor/Vascular Permeability Factor Augments Nitric Oxide Release From Quiescent Rabbit and Human Vascular Endothelium." <u>Circulation</u> , 95:1030-1037 (1997)		
	75	Verhoeyen, M. et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity" <u>Science</u> 239:1534-1536 (Mar 25, 1988)		
	76	Waltenberger et al., "Different Signal Transduction Properties of KDR and Flt1, Two Receptors for Vascular Endothelial Growth Factor." <u>J. Bio. Chem.</u> 269(43):26988-26995 (Oct 28, 1994)		
	77	Wiesmann et al., "Crystal Structure at 1.7 A Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor." <u>Cell.</u> 91:695-704 (Nov 1997)		
	78	Wu et al., "VEGF Induces NO-Dependent Hyperpermeability in Coronary Venules." Am. J. Physiol. 271:H2735-H2739 (1996)		
	79	Yang et al., "Effects of Vascular Endothelial Growth Factor on F Cardiovasc. Pharmacol. 27:838-844 (1996)	demodynamics and Card	diac Performance." J.
RBL	80	Ziche et al., "Nitric Oxide Synthase Lies Downstream from Vascular Endothelial Growth Factor-Induced bu not Basic Fibroblast Growth Factor-Induced Angiogenesis." <u>J. Clin. Invest.</u> 99:2625-2634 (Jun 1997)		
m.,,,!-				
Examiner Raylor B. Kayhart Date Considered 12/10/0.3				

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.